BR112013022213A2 - administração parenteral de tapentadol - Google Patents

administração parenteral de tapentadol

Info

Publication number
BR112013022213A2
BR112013022213A2 BR112013022213A BR112013022213A BR112013022213A2 BR 112013022213 A2 BR112013022213 A2 BR 112013022213A2 BR 112013022213 A BR112013022213 A BR 112013022213A BR 112013022213 A BR112013022213 A BR 112013022213A BR 112013022213 A2 BR112013022213 A2 BR 112013022213A2
Authority
BR
Brazil
Prior art keywords
tapentadol
parenteral administration
pharmaceutical composition
acceptable salt
value
Prior art date
Application number
BR112013022213A
Other languages
English (en)
Inventor
Wulsten Eva
Schiene Klaus
Schiller Marc
Bloms-Funke Petra
Carolus Augusta Embechts Roger
Karine Katrien Inghelbrecht Sabine
Christoph Thomas
Feil Ulrich
Reinhold Ulrich
Original Assignee
Gruenenthal Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal Gmbh filed Critical Gruenenthal Gmbh
Publication of BR112013022213A2 publication Critical patent/BR112013022213A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof

Abstract

resumo patente de invenção: "administração parenteral de tapentadol". a presente invenção refere-se a uma composição farmacêutica aquosa adaptada para administração parenteral de tapentadol ou um sal fisiologicamente aceitável do mesmo que tem um valor de ph de pelo menos 5,4.
BR112013022213A 2011-03-04 2012-03-02 administração parenteral de tapentadol BR112013022213A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161449317P 2011-03-04 2011-03-04
EP11003602 2011-05-03
PCT/EP2012/000905 WO2012119728A1 (en) 2011-03-04 2012-03-02 Parenteral administration of tapentadol

Publications (1)

Publication Number Publication Date
BR112013022213A2 true BR112013022213A2 (pt) 2017-05-02

Family

ID=44653043

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013022213A BR112013022213A2 (pt) 2011-03-04 2012-03-02 administração parenteral de tapentadol

Country Status (23)

Country Link
US (3) US20120225951A1 (pt)
EP (2) EP2680833B1 (pt)
JP (4) JP2014510067A (pt)
KR (2) KR101970468B1 (pt)
CN (2) CN107088226A (pt)
AU (2) AU2012224953C1 (pt)
BR (1) BR112013022213A2 (pt)
CA (1) CA2828635C (pt)
CY (1) CY1117426T1 (pt)
DK (1) DK2680833T3 (pt)
EA (2) EA028149B1 (pt)
ES (1) ES2573414T3 (pt)
HK (1) HK1194964A1 (pt)
HR (1) HRP20160400T1 (pt)
HU (1) HUE027514T2 (pt)
IL (1) IL227825A (pt)
MX (1) MX348831B (pt)
PL (1) PL2680833T3 (pt)
PT (1) PT2680833E (pt)
RS (1) RS54711B1 (pt)
SI (1) SI2680833T1 (pt)
WO (1) WO2012119728A1 (pt)
ZA (1) ZA201306479B (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011267474B2 (en) 2010-06-15 2016-05-26 Grünenthal GmbH Pharmaceutical combination for the treatment of pain
PL3287123T3 (pl) 2011-03-04 2020-11-02 Grünenthal GmbH Wodny preparat farmaceutyczny tapentadolu do podawania doustnego
MX353456B (es) * 2011-07-29 2018-01-15 Gruenenthal Gmbh Administracion intratecal o epidural de 3-[(1s,2s)-3-(dimetilamino )-1-etil-2-metilpropil]fenol.
BR112015009839A2 (pt) * 2012-11-01 2017-07-11 Torrent Pharmaceuticals Ltd composição farmacêutica de tapentadol para administração parenteral
EP2808319A1 (en) 2013-05-31 2014-12-03 Arevipharma GmbH 3-[3-(Dimethylamino)-1-ethyl-2-methylpropyl]phenol resin complex
EP2845625A1 (en) 2013-09-04 2015-03-11 Grünenthal GmbH Tapentadol for use in the treatment of fibromyalgia and chronic fatigue syndrome
CN103735500B (zh) * 2014-01-28 2016-01-20 江苏华泽医药科技有限公司 盐酸他喷他多注射液及其制备方法
EP3479823B1 (en) 2015-03-27 2020-09-09 Grünenthal GmbH Stable formulation for parenteral administration of tapentadol
AU2017329964B2 (en) * 2016-09-23 2022-10-06 Grünenthal GmbH Stable formulation for parenteral administration of Tapentadol
EP3585370A1 (en) 2017-02-23 2020-01-01 Grünenthal GmbH Tapentadol as local anesthetic
EP4011369A1 (en) * 2020-12-14 2022-06-15 G.L. Pharma GmbH Aqueous pharmaceutical composition comprising tapentadol tartrate

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8334422D0 (en) * 1983-12-23 1984-02-01 Sterwin Ag Composition
DE4426245A1 (de) 1994-07-23 1996-02-22 Gruenenthal Gmbh 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung
US6399087B1 (en) * 2000-12-20 2002-06-04 Amphastar Pharmaceuticals, Inc. Propofol formulation with enhanced microbial inhibition
DE10109763A1 (de) 2001-02-28 2002-09-05 Gruenenthal Gmbh Pharmazeutische Salze
JP4905616B2 (ja) * 2001-04-19 2012-03-28 ライオン株式会社 ソフトコンタクトレンズ用点眼剤
PE20030527A1 (es) 2001-10-24 2003-07-26 Gruenenthal Chemie Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen
US20030191187A1 (en) * 2002-04-01 2003-10-09 Lee Fang Yu Injectable pharmaceutical composition containing a non-steroidal anti-inflammatory drug and method for preparing the same
US20040180915A1 (en) * 2003-03-14 2004-09-16 Xanodyne Pharmacal, Inc. Methadone-containing compositions for parenteral administration and method of use thereof
SI1612203T1 (sl) * 2004-06-28 2007-12-31 Gruenenthal Chemie Kristalne oblike (-)-(1R,2R)-3-(3-dimetilamino-1-etil-2-metilpropil)-fenol hidroklorida
PL1786403T3 (pl) 2004-07-01 2013-10-31 Gruenenthal Gmbh Doustna postać dawki zabezpieczona przed nadużywaniem zawierająca (1R, 2R)-3-(3-dimetyloamino-1-etylo0-2-metylo-propylo)fenol
WO2006116626A2 (en) * 2005-04-28 2006-11-02 Theraquest Biosciences Llc Methods and compositions for treating pain
DK2012764T3 (da) * 2006-04-28 2011-02-28 Gruenenthal Gmbh Farmaceutisk kombination omfattende 3-(3-dimethylamino-1-ethyl-2methyl-propyl)-phenol og paracetamol
WO2007128412A1 (en) * 2006-04-28 2007-11-15 Grünenthal GmbH Pharmaceutical combination comprising 3- (3-dimethylamin0-1-ethyl-2-methyl-pr0pyl) -phenol and an nsaid
ES2339403T3 (es) * 2006-07-24 2010-05-19 Janssen Pharmaceutica Nv Preparacion de (2r,3r)-3-(3-metoxifenil)-n,n,2-trimetilpentanamina.
EP1905440A1 (de) * 2006-09-06 2008-04-02 Boehringer Ingelheim Pharma GmbH & Co. KG Verwendung einer pharmazeutischen Zusammensetzung enthaltend ein Anticholinergikum zur Abtötung von Mikroorganismen und zur Behandlung von Atemwegsinfektionen
TWI394564B (zh) * 2006-09-21 2013-05-01 Alcon Res Ltd 自行保存型水性藥學組成物
DE102007012165A1 (de) * 2007-03-12 2008-09-18 Grünenthal GmbH Verwendung von 1-Phenyl-3-dimethylamino-propanverbindungen zur Therapie des Neuropathieschmerzes
JP2008266168A (ja) * 2007-04-18 2008-11-06 Teika Seiyaku Kk 眼科用剤
EP1985292A1 (en) * 2007-04-23 2008-10-29 Grünenthal GmbH Titration of tapentadol
MX360289B (es) 2007-11-23 2018-10-29 Gruenenthal Gmbh Composiciones de tapentadol.
AU2009207796B2 (en) 2008-01-25 2014-03-27 Grunenthal Gmbh Pharmaceutical dosage form
PT2331210E (pt) * 2008-09-05 2014-08-25 Gruenenthal Gmbh Combinação farmacêutica de 3-(3-dimetilamino-1-etil-2- metilpropil)fenol e um antiepiléptico
EP2246044A1 (en) * 2009-04-21 2010-11-03 Pierre Fabre Dermo-Cosmétique Paediatric solutions comprising a beta-blocker
US20100272815A1 (en) 2009-04-28 2010-10-28 Actavis Group Ptc Ehf Amorphous form of tapentadol hydrochloride

Also Published As

Publication number Publication date
WO2012119728A1 (en) 2012-09-13
DK2680833T3 (en) 2016-05-23
CN103501775A (zh) 2014-01-08
JP2018021050A (ja) 2018-02-08
KR101903351B1 (ko) 2018-10-04
US20160106688A1 (en) 2016-04-21
AU2012224953A1 (en) 2013-09-19
HK1194964A1 (zh) 2014-10-31
EP2680833B1 (en) 2016-03-02
KR20140017587A (ko) 2014-02-11
CN107088226A (zh) 2017-08-25
MX348831B (es) 2017-06-30
SI2680833T1 (sl) 2016-06-30
EP3025710A1 (en) 2016-06-01
RS54711B1 (en) 2016-08-31
ZA201306479B (en) 2014-05-28
AU2017202214A1 (en) 2017-04-27
JP6837944B2 (ja) 2021-03-03
CY1117426T1 (el) 2017-04-26
CA2828635A1 (en) 2012-09-13
HRP20160400T1 (hr) 2016-05-20
CA2828635C (en) 2020-01-14
IL227825A (en) 2017-07-31
US20200215003A1 (en) 2020-07-09
IL227825A0 (en) 2013-09-30
PL2680833T3 (pl) 2016-08-31
EA201300990A1 (ru) 2014-02-28
JP2023075244A (ja) 2023-05-30
ES2573414T3 (es) 2016-06-07
US20120225951A1 (en) 2012-09-06
KR101970468B1 (ko) 2019-04-19
EA024193B1 (ru) 2016-08-31
JP2014510067A (ja) 2014-04-24
JP2022033863A (ja) 2022-03-02
KR20180064568A (ko) 2018-06-14
PT2680833E (pt) 2016-06-09
AU2017202214B2 (en) 2019-02-14
EA028149B1 (ru) 2017-10-31
AU2012224953B2 (en) 2017-01-05
EA201600088A1 (ru) 2016-07-29
AU2012224953C1 (en) 2017-07-13
EP2680833A1 (en) 2014-01-08
MX2013010046A (es) 2013-12-16
HUE027514T2 (en) 2016-10-28

Similar Documents

Publication Publication Date Title
BR112013022213A2 (pt) administração parenteral de tapentadol
BR112015022972A2 (pt) composição farmacêutica de cloridrato de s-cetamina
BR112013022495A2 (pt) formulação farmacêutica aquosa de tapentadol para administração oral
BR112014009031A2 (pt) formulações de etanercept estabilizadas com íons de metais
BR112014019667A2 (pt) formulação de anticorpo abeta
BR112015018738A8 (pt) compostos de tetra-hidropirrolotiazina, seus usos, e composição farmacêutica
BR112015000229A2 (pt) formulações aquosas estáveis de etanercept
BR112016003348A2 (pt) composto ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica e usos de quantidade efetiva de composto ou sal farmaceuticamente aceitável do mesmo ou composição farmacêutica
PH12015500587A1 (en) Combination of regorafenib and acetylsalicylic acid for treating cancer
BR112015012693A2 (pt) derivados de pirimidona e seu uso no tratamento, melhora ou prevenção de uma doença viral
BR112016011755A2 (pt) derivado de ureia ou sal farmacologicamente aceitável do mesmo
BR112014001600A2 (pt) composto inibidor do trajeto de sinalização notch
BR112015016930A2 (pt) formulações farmacêuticas estabilizadas de análogos de insulina e/ou derivados de insulina
BR112014031204A2 (pt) derivados deuterados de ruxolitinib
BR112015011430A2 (pt) composição para liberação imediata e prolongada
BR112015017525A2 (pt) peptídeo modificado, sal de um peptídeo modificado, medicamento, e, métodos para tratar ou aliviar uma doença cardiovascular e para produzir um peptídeo modificado
MX344473B (es) Composicion farmaceutica acuosa semisolida que contiene tapentadol.
BR112014005025A2 (pt) composição farmacêutica para uso no tratamento de uma doença neurodegenerativa
BR112015021332A2 (pt) sal de sódio de ácido (2s, 5r)-6-benzilóxi-7-oxo-1,6-diaza-biciclo [3.2.1] octano-2-carboxílico e sua preparação
BR112015026967A8 (pt) fenoxietil di-hidro-1h-isoquinolina, seus usos, e composição farmacêutica
BR112014026305A2 (pt) derivado de quinazolidinadiona
BR112019004236A2 (pt) compostos para tratar doenças associadas a uma disfunção mitocondrial
BR112014004732A2 (pt) composto benzotiazolona
BR112015025058A2 (pt) composição farmacêutica capaz de controlar facilmente o padrão de dissolução de lacosamida ou de um sal farmaceuticamente aceitável da mesma
UY35183A (es) Composición farmacéutica oftalmológica tópica que contiene regorafenib

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL